Ofatumumab treatment in new‐onset narcolepsy type 1 following <scp>SARS</scp>‐<scp>CoV</scp>‐2 infection
The efficacy of ofatumumab in this case provides additional support for an autoimmune etiology in narcolepsy with cataplexy, highlighting the potential involvement of B-cells in its pathophysiology. This understanding will aid in the development of specific immunotherapeutic strategies for early implementation upon disease onset.
Authors
- Y F Liu (ORCID: https://orcid.org/0000-0003-2469-3668)
- Xiaoli Wang (ORCID: https://orcid.org/0000-0002-0640-9865)
- Na Yuan (ORCID: https://orcid.org/0000-0003-4358-1952)
- Xinbo Zhang (ORCID: https://orcid.org/0009-0007-7799-7880)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1002/acn3.52284
- Citations
- 1
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.34
Funders
- National Key Research and Development Program of China